| An overview of integration of therapy for congestive heart failure. | |
| | |
MedLine Citation:
|
PMID: 2478815 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Patients with symptoms of congestive heart failure look to treatment to relieve symptoms, improve the quality of life, and prolong life. They prefer a convenient dosing schedule, with minimal side effects and low cost. A wide variety of agents are available to treat patients with congestive heart failure. The three major classes of drugs that improve heart failure include the diuretics, inotropic drugs, and vasodilators. It appears that any one of these three classes are potential first-line candidates for treating patients with congestive heart failure. Patients with edema usually require long-term therapy with diuretic agents. Since the vasodilators are the only class of drugs which have been shown to prolong life, they should be used routinely in the management of patients with congestive heart failure. Since all three classes of drugs have additive beneficial hemodynamic effects, it makes sense to consider the use of all three in patients with at least moderate to severe heart failure. At the moment unanswered questions include the role of antiarrhythmic agents in reducing the incidence of sudden death, and the use of potent new inotropic vasodilators. Overall, the current therapeutic approach to patients with heart failure is effective in relieving symptoms, improving exercise tolerance and in prolonging life. |
| | |
Authors:
|
W W Parmley |
Related Documents
:
|
2961425 - Responses of vasoactive hormones in congestive cardiac failure. 11251125 - Coronary artery surgery for ischemic heart failure: risks, benefits, and the importance... 7713105 - Biochemical and electrophysiological alterations underlying ventricular arrhythmias in ... 12563565 - Vasopeptidase inhibitors in heart failure. 3050135 - Molecular biology in cardiology, a paradigmatic shift. 10953265 - Management of atrial flutter. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Journal of cardiovascular pharmacology Volume: 14 Suppl 5 ISSN: 0160-2446 ISO Abbreviation: J. Cardiovasc. Pharmacol. Publication Date: 1989 |
Date Detail:
|
Created Date: 1989-12-19 Completed Date: 1989-12-19 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7902492 Medline TA: J Cardiovasc Pharmacol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: S73-7 Citation Subset: IM |
Affiliation:
|
Department of Medicine, University of California, San Francisco. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Heart Failure
/
drug therapy,
physiopathology,
therapy* Humans |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Mechanical characteristics of the failing left ventricle.
Next Document: Do cultured vascular smooth muscle cells resemble those of the artery wall? If not, why not?